31-Mar-2026
No headlines found.
Globe Newswire (Mon, 23-Mar 7:30 AM ET)
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Globe Newswire (Tue, 24-Feb 8:00 AM ET)
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Globe Newswire (Thu, 5-Feb 8:00 AM ET)
Cabaletta Bio Announces 2026 Strategic Priorities
Globe Newswire (Mon, 12-Jan 8:00 AM ET)
Business Wire (Mon, 12-Jan 7:30 AM ET)
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Cabaletta Bio trades on the NASDAQ stock market under the symbol CABA.
As of March 31, 2026, CABA stock price climbed to $2.69 with 1,703,235 million shares trading.
CABA has a beta of 3.86, meaning it tends to be more sensitive to market movements. CABA has a correlation of 0.29 to the broad based SPY ETF.
CABA has a market cap of $299.46 million. This is considered a Small Cap stock.
Last quarter Cabaletta Bio reported $0 in Revenue and -$.40 earnings per share. This fell short of revenue expectation by $-833,330 and exceeded earnings estimates by $.06.
In the last 3 years, CABA traded as high as $26.35 and as low as $.99.
The top ETF exchange traded funds that CABA belongs to (by Net Assets): VTI, VXF, IBB, IWC, DFAS.
CABA has outperformed the market in the last year with a return of +73.5%, while the SPY ETF gained +18.4%. In the last 3 month period, CABA beat the market returning +25.1%, while SPY returned -5.1%. However, in the most recent 2 weeks CABA has underperformed the stock market by returning -15.9%, while SPY returned -2.5%.
CABA support price is $2.34 and resistance is $2.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CABA shares will trade within this expected range on the day.